Published in PLoS One on March 26, 2015
The Value of Macrolide-Based Regimens for Community-Acquired Pneumonia. Curr Infect Dis Rep (2015) 0.76
The non-antibiotic macrolide EM900 inhibits rhinovirus infection and cytokine production in human airway epithelial cells. Physiol Rep (2015) 0.75
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2007) 47.86
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J (2004) 16.84
Global burden of COPD: risk factors, prevalence, and future trends. Lancet (2007) 9.50
Azithromycin for prevention of exacerbations of COPD. N Engl J Med (2011) 8.66
Azithromycin and the risk of cardiovascular death. N Engl J Med (2012) 8.18
Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med (2004) 6.21
Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med (2011) 5.69
Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med (2008) 4.33
Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med (2006) 4.11
Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax (2012) 4.06
Guidelines for the management of adult lower respiratory tract infections--full version. Clin Microbiol Infect (2011) 2.99
Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev (2013) 2.95
Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med (2008) 2.66
Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ (2013) 2.43
Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration (2010) 2.00
Erythromycin and common cold in COPD. Chest (2001) 1.78
Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med (2014) 1.73
Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med (2014) 1.68
Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial. Thorax (2006) 1.52
Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery. Arch Bronconeumol (2012) 1.29
Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy. Pulm Pharmacol Ther (2009) 1.23
Chemistry and mode of action of macrolides. J Antimicrob Chemother (1993) 1.18
Seasonal distribution of COPD exacerbations in the Prevention of Exacerbations with Tiotropium in COPD trial. Chest (2013) 1.09
Long-term macrolide treatment for chronic respiratory disease. Eur Respir J (2012) 1.07
Long-term macrolide treatment of chronic inflammatory airway diseases: risks, benefits and future developments. Clin Exp Allergy (2012) 1.02
[Prospective, comparative study (1994-1998) of the influence of short-term prophylactic treatment with azithromycin on patients with advanced COPD]. Rev Esp Quimioter (2000) 1.01
The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. Respir Med (2005) 1.01
Preventing acute exacerbations and hospital admissions in COPD. Chest (2013) 0.95
Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis. Pulm Pharmacol Ther (2009) 0.93
Macrolide effects on the prevention of COPD exacerbations. Eur Respir J (2012) 0.91
Macrolide antibiotics broadly and distinctively inhibit cytokine and chemokine production by COPD sputum cells in vitro. Pharmacol Res (2011) 0.89
Immunomodulatory properties of macrolides: overview and historical perspective. Am J Med (2004) 0.86
The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial. PLoS One (2014) 0.84
Macrolide therapy decreases chronic obstructive pulmonary disease exacerbation: a meta-analysis. Respiration (2013) 0.83
Azithromycin and cough-specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respir Res (2013) 0.82
A meta-analysis on the prophylactic use of macrolide antibiotics for the prevention of disease exacerbations in patients with Chronic Obstructive Pulmonary Disease. Respir Med (2013) 0.82
The role of macrolides in noncystic fibrosis bronchiectasis. Pulm Med (2011) 0.76
In vitro effects of tigecycline in combination with colistin (polymyxin E) and sulbactam against multidrug-resistant Acinetobacter baumannii. J Antibiot (Tokyo) (2013) 0.84
In vitro activity of fosfomycin in combination with colistin against clinical isolates of carbapenem-resistant Pseudomas aeruginosa. J Antibiot (Tokyo) (2015) 0.81
A meta-analysis of metronidazole and vancomycin for the treatment of Clostridium difficile infection, stratified by disease severity. Braz J Infect Dis (2015) 0.80
Efficacy of polymyxins in the treatment of carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis. Braz J Infect Dis (2015) 0.78
Effect of proton pump inhibitors on in vitro activity of tigecycline against several common clinical pathogens. PLoS One (2014) 0.75
A pharmacodynamic simulation to evaluate tigecycline in treatment of nosocomial pneumonia caused by multidrug-resistant Acinetobacter baumannii. Pak J Pharm Sci (2014) 0.75